Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12999036 | 0.91 | LMNA (0.58) | NR4A2LMNAHPGDMRGPRX4MAPK14 | |
| SCHEMBL2909026 | 0.87 | NR4A2 (0.63) | NR4A2MRGPRX4MAOBPTGER4HTT | |
| SCHEMBL3766516 | 0.87 | RXRA (0.65) | NR4A2MRGPRX4MAOBPTGER4HTT | |
| SCHEMBL2909519 | 0.85 | PPARG (0.56) | LMNAHPGDMRGPRX4MAOBPTGER4 | |
| SCHEMBL2907948 | 0.85 | MMP13 (0.62) | LMNAMRGPRX4PTGER4HTTCYP1A2 | |
| SCHEMBL2905853 | 0.83 | NR4A2 (0.62) | NR4A2MRGPRX4PTGER4HTTMEN1 | |
| SCHEMBL2909423 | 0.82 | PTGER4 (0.55) | NR4A2PTGER4MEN1KMT2APOLB | |
| SCHEMBL2910612 | 0.81 | RXRA (0.64) | NR4A2MRGPRX4MAOBPTGER4HTT | |
| SCHEMBL2906311 | 0.80 | NR4A2 (0.62) | NR4A2MAOBPTGER4HTTCYP1A2 | |
| SCHEMBL14014028 | 0.80 | NR4A2 (1.00) | NR4A2MRGPRX4MAOBFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220029-B1 | Benzamide compounds and their use as prostaglandin E4 receptor agonists | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | claimed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | claimed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | claimed |
| EP-2220029-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-08-25 | — | — | EP | claimed |
| WO-2009056582-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | claimed |
| EP-2220029-B1 | Benzamide compounds and their use as prostaglandin E4 receptor agonists | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| EP-2220029-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009056582-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009056582-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305166-A1 | NOVEL COMPOUNDS | F12, C1R, RPS4X | NR4A2 557/4885LMNA 1702/4885HPGD 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.